GNTLF: AI 评分 44/100 — AI 分析 (4月 2026)

Genetic Technologies Limited is a molecular diagnostics company focused on predictive testing and assessment tools for women's health. Their lead product, BREVAGenplus, assesses non-hereditary breast cancer risk.

Key Facts: AI Score: 44/100 Sector: Healthcare

公司概况

概要：

Genetic Technologies Limited, operating in the medical diagnostics sector, provides predictive testing tools, primarily BREVAGenplus, for assessing breast cancer risk. The company targets healthcare professionals in breast health and imaging centers, offering genetic testing services across medical, animal, forensic, and plant applications, with research collaborations enhancing its market reach.

GNTLF是做什么的？

Genetic Technologies Limited, founded in 1987 and headquartered in Fitzroy, Australia, is a molecular diagnostics company specializing in predictive testing and assessment tools. The company primarily focuses on women's health, offering products and services to help physicians manage and mitigate health risks. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer, marketed to healthcare professionals, breast health centers, imaging centers, obstetricians, gynecologists, and breast surgeons in both Australia and the United States. Beyond BREVAGenplus, Genetic Technologies offers a range of cancer risk assessment tests under the GeneType brand, including tests for colorectal and breast cancer. The company is also actively developing risk assessment tests for other diseases, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma, expanding its portfolio to address a broader spectrum of health concerns. Genetic Technologies also provides genetic testing services across various sectors, including medical, animal, forensic, and plant testing, diversifying its revenue streams and market presence. The company maintains research and collaboration agreements with several institutions, including the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom, to drive innovation and expand its scientific knowledge base.

GNTLF的投资论点是什么？

Genetic Technologies Limited presents an investment opportunity within the growing molecular diagnostics market, particularly in predictive testing for women's health. The company's BREVAGenplus product and GeneType tests address a critical need for early risk assessment in breast and colorectal cancer. With a market capitalization of $1.34 billion, the company's growth potential is tied to expanding the adoption of its existing tests and successfully developing new risk assessment tools for other diseases. Key catalysts include ongoing research collaborations and potential regulatory approvals for new products. However, the company's negative P/E ratio of -0.45 and a profit margin of -156.8% indicate financial challenges that require careful consideration. Success hinges on achieving profitability through increased sales and efficient cost management.

GNTLF在哪个行业运营？

Genetic Technologies Limited operates in the medical diagnostics and research industry, a sector experiencing growth driven by advancements in genomics and personalized medicine. The market is competitive, with companies like CHIZF, CMOPF, CSPHF, EVOTF, and MRCHF also offering diagnostic solutions. The demand for predictive and personalized healthcare is increasing, fueled by a growing awareness of preventive medicine and the potential for early disease detection. Genetic Technologies is positioned to capitalize on these trends with its focus on risk assessment tests, particularly in women's health. The industry is also subject to regulatory oversight and requires continuous innovation to stay competitive.

Medical - Diagnostics & Research

Healthcare

GNTLF有哪些增长机遇？

Expanding the GeneType product line for colorectal cancer represents a significant growth opportunity. With increasing awareness of colorectal cancer screening and the need for personalized risk assessment, Genetic Technologies can leverage its existing platform to capture a larger share of this market. Successful commercialization and adoption by healthcare providers could drive substantial revenue growth. The global colorectal cancer diagnostics market is projected to reach billions of dollars, offering a substantial addressable market.
Developing and commercializing risk assessment tests for cardiovascular disease presents a major growth avenue. Cardiovascular diseases are a leading cause of death globally, and early risk assessment is crucial for prevention and management. Genetic Technologies can leverage its expertise in genomics to develop innovative tests that identify individuals at high risk. Successful development and adoption of these tests could significantly expand the company's market reach and revenue streams. The cardiovascular diagnostics market represents a multi-billion dollar opportunity.
Geographic expansion into new markets, particularly in Europe and Asia, offers substantial growth potential. By partnering with local distributors and healthcare providers, Genetic Technologies can introduce its BREVAGenplus and GeneType tests to a broader customer base. Adapting its products and marketing strategies to meet the specific needs of different regions can drive adoption and revenue growth. International expansion requires careful planning and execution, but the potential rewards are significant.
Leveraging research collaborations to develop new diagnostic tests and improve existing ones is crucial for long-term growth. By partnering with leading research institutions, Genetic Technologies can access cutting-edge technologies and scientific expertise. These collaborations can accelerate the development of innovative tests for a range of diseases, enhancing the company's product portfolio and competitive advantage. Successful research collaborations can also lead to publications and presentations that enhance the company's reputation and credibility.
Expanding genetic testing services beyond human health into animal, forensic, and plant testing provides diversification and growth opportunities. These markets offer unique applications for genetic testing, such as disease detection in animals, forensic analysis in criminal investigations, and crop improvement in agriculture. By leveraging its expertise in genetic testing, Genetic Technologies can tap into these niche markets and generate additional revenue streams. Diversification can also reduce the company's reliance on the human health market and mitigate risks.

Market Cap of $1.34B reflecting investor valuation of the company's future potential in the molecular diagnostics market.
Gross Margin of 50.9% indicating a strong ability to control the direct costs associated with its testing services.
BREVAGenplus is a clinically validated risk assessment test for non-hereditary breast cancer, providing a key revenue stream.
Research collaborations with institutions like the University of Melbourne and Memorial Sloan Kettering enhance the company's innovation pipeline.
Beta of 0.25 suggesting the stock is significantly less volatile than the overall market.

GNTLF提供哪些产品和服务？

Develop and market BREVAGenplus, a risk assessment test for non-hereditary breast cancer.
Offer GeneType tests for colorectal and breast cancer risk assessment.
Develop risk assessment tests for cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma.
Provide genetic testing services for medical applications.
Offer genetic testing services for animal applications.
Provide genetic testing services for forensic applications.
Offer genetic testing services for plant testing.
Engage in research and collaboration agreements with universities and research institutions.

GNTLF如何赚钱？

Generate revenue through the sale of BREVAGenplus and GeneType tests to healthcare providers and patients.
Earn revenue from genetic testing services provided to medical, animal, forensic, and plant sectors.
Collaborate with research institutions to develop new diagnostic tests and improve existing ones.
Expand market reach through partnerships with distributors and healthcare providers in different regions.

Healthcare professionals, including breast health specialists, imaging centers, obstetricians, gynecologists, and breast surgeons.
Patients seeking risk assessment for breast and colorectal cancer.
Medical institutions requiring genetic testing services.
Animal breeders and veterinarians requiring genetic testing services.
Forensic laboratories requiring genetic testing services.
Agricultural companies requiring genetic testing services.

Clinically validated BREVAGenplus test provides a competitive advantage in the breast cancer risk assessment market.
Proprietary GeneType tests offer differentiated solutions for colorectal and breast cancer risk assessment.
Research collaborations with leading institutions enhance innovation and scientific credibility.
Diversified genetic testing services across medical, animal, forensic, and plant sectors provide multiple revenue streams.

什么因素可能推动GNTLF股价上涨？

Upcoming: Potential regulatory approvals for new diagnostic tests.
Ongoing: Expansion of the GeneType product line for colorectal cancer.
Ongoing: Research collaborations with leading institutions.
Ongoing: Geographic expansion into new markets.

GNTLF的主要风险是什么？

Potential: Competition from larger diagnostic companies.
Potential: Regulatory changes affecting genetic testing.
Potential: Technological advancements rendering existing tests obsolete.
Ongoing: Negative P/E ratio and profit margin.
Ongoing: OTC market listing.

GNTLF的核心优势是什么？

Clinically validated BREVAGenplus test.
Proprietary GeneType tests.
Research collaborations with leading institutions.
Diversified genetic testing services.

GNTLF的劣势是什么？

Negative P/E ratio and profit margin.
Limited market presence compared to larger competitors.
Dependence on a few key products.
OTC market listing.

GNTLF有哪些机遇？

Expanding the GeneType product line for colorectal cancer.
Developing risk assessment tests for cardiovascular disease.
Geographic expansion into new markets.
Leveraging research collaborations to develop new diagnostic tests.

GNTLF面临哪些威胁？

Competition from larger diagnostic companies.
Regulatory changes affecting genetic testing.
Technological advancements rendering existing tests obsolete.
Economic downturn impacting healthcare spending.

GNTLF的竞争对手是谁？

CHF Solutions Inc — CHF Solutions focuses on treating fluid overload in heart failure patients. — (CHIZF)
Compugen Ltd — Compugen is an immunotherapy company discovering novel drug targets. — (CMOPF)
Cresopharma Inc — Cresopharma focuses on cannabis-based pharmaceutical products. — (CSPHF)
Evotec SE — Evotec is a drug discovery and development company. — (EVOTF)
Mercia Technologies PLC — Mercia Technologies invests in and supports innovative technology businesses. — (MRCHF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Kevin Camilleri
Headquarters: Fitzroy, AU
Employees: 55
Founded: 2000

AI Insight

AI analysis pending for GNTLF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Genetic Technologies Limited do?

Genetic Technologies Limited is a molecular diagnostics company focused on providing predictive testing and assessment tools, primarily for women's health. Their main product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. Additionally, they offer GeneType tests for colorectal and breast cancer, and are developing tests for other diseases like cardiovascular disease and type 2 diabetes. The company also provides genetic testing services for medical, animal, forensic, and plant applications, diversifying their revenue streams within the healthcare sector.

What do analysts say about GNTLF stock?

As of March 16, 2026, a comprehensive analyst consensus for Genetic Technologies Limited (GNTLF) is not readily available. However, key valuation metrics to consider include the company's market capitalization of $1.34 billion, a negative P/E ratio of -0.45, and a gross margin of 50.9%. Growth considerations should focus on the company's ability to expand its product portfolio, increase market penetration, and achieve profitability. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.

What are the main risks for GNTLF?

The main risks for Genetic Technologies Limited include intense competition from larger diagnostic companies, potential regulatory changes impacting genetic testing, and the risk of technological advancements rendering their existing tests obsolete. The company's negative P/E ratio and profit margin also pose financial risks. Furthermore, being listed on the OTC market introduces additional risks related to liquidity, volatility, and limited disclosure. Investors should carefully consider these risks before investing in GNTLF.